170 related articles for article (PubMed ID: 17048519)
1. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines.
Serpe L; Guido M; Canaparo R; Muntoni E; Cavalli R; Panzanelli P; Della Pepal C; Bargoni A; Mauro A; Gasco MR; Eandi M; Zara GP
J Nanosci Nanotechnol; 2006; 6(9-10):3062-9. PubMed ID: 17048519
[TBL] [Abstract][Full Text] [Related]
2. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
3. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Muntoni E; Biasibetti E; Capucchio MT; Valazza A; Panciani PP; Lanotte M; Schiffer D; Annovazzi L; Caldera V; Mellai M; Riganti C
J Pharm Sci; 2014 Jul; 103(7):2157-2165. PubMed ID: 24824141
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
5. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
8. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
9. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
Serpe L; Catalano MG; Cavalli R; Ugazio E; Bosco O; Canaparo R; Muntoni E; Frairia R; Gasco MR; Eandi M; Zara GP
Eur J Pharm Biopharm; 2004 Nov; 58(3):673-80. PubMed ID: 15451544
[TBL] [Abstract][Full Text] [Related]
11. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
12. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
13. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
14. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles.
Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA
Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339
[TBL] [Abstract][Full Text] [Related]
15. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
18. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
19. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
